CJASN:急性肾衰患者透析能使患者生存获益(倾向匹配分析)

2014-04-28 佚名 中国医学论坛报

美国学者研究发现,对于血清肌酐有较大程度升高的急性肾损伤(AKI)患者,起始透析与生存率升高相关,相反,对于血清肌酐较低的AKI患者,起始透析与死亡率升高相关。论文4月7日在线发表于《美国肾脏病学会临床杂志》(Clin J Am Soc Nephrol)。 研究纳入严重AKI患者6119例,其中602例接受了透析治疗。研究结果表明,经倾向性评分匹配后,透析与非透析两组患者间的协变量均衡良好,

美国学者研究发现,对于血清肌酐有较大程度升高的急性肾损伤(AKI)患者,起始透析与生存率升高相关,相反,对于血清肌酐较低的AKI患者,起始透析与死亡率升高相关。论文4月7日在线发表于《美国肾脏病学会临床杂志》(Clin J Am Soc Nephrol)。

研究纳入严重AKI患者6119例,其中602例接受了透析治疗。研究结果表明,经倾向性评分匹配后,透析与非透析两组患者间的协变量均衡良好,二者间的死亡总风险比(HR)为1.01(P=0.89)。

血清肌酐浓度每增加1mg/dl,则透析可使生存获益增加20%(P=0.001)。在校正疾病严重度后,该结果仍不变。当血清肌酐浓度≥3.8mg/dl时,透析的益处超过其弊端。

原始出处:

Wilson FP, Yang W, Machado CA, Mariani LH, Borovskiy Y, Berns JS, Feldman HI.Dialysis versus Nondialysis in Patients with AKI: A Propensity-Matched Cohort Study.Clin J Am Soc Nephrol. 2014 Apr;9(4):673-81

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=34393, encodeId=08093439315, content=这个当然, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:21:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932497, encodeId=3749193249ec0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 07 23:20:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941247, encodeId=18f0194124e0d, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 06 19:20:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006922, encodeId=cd562006922e4, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Jun 24 08:20:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783229, encodeId=5b2c1e83229ce, content=<a href='/topic/show?id=2f7d4e816b' target=_blank style='color:#2F92EE;'>#CJASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4781, encryptionId=2f7d4e816b, topicName=CJASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Aug 14 13:20:00 CST 2014, time=2014-08-14, status=1, ipAttribution=)]
    2015-08-04 sundong

    这个当然

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=34393, encodeId=08093439315, content=这个当然, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:21:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932497, encodeId=3749193249ec0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 07 23:20:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941247, encodeId=18f0194124e0d, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 06 19:20:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006922, encodeId=cd562006922e4, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Jun 24 08:20:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783229, encodeId=5b2c1e83229ce, content=<a href='/topic/show?id=2f7d4e816b' target=_blank style='color:#2F92EE;'>#CJASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4781, encryptionId=2f7d4e816b, topicName=CJASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Aug 14 13:20:00 CST 2014, time=2014-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=34393, encodeId=08093439315, content=这个当然, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:21:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932497, encodeId=3749193249ec0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 07 23:20:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941247, encodeId=18f0194124e0d, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 06 19:20:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006922, encodeId=cd562006922e4, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Jun 24 08:20:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783229, encodeId=5b2c1e83229ce, content=<a href='/topic/show?id=2f7d4e816b' target=_blank style='color:#2F92EE;'>#CJASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4781, encryptionId=2f7d4e816b, topicName=CJASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Aug 14 13:20:00 CST 2014, time=2014-08-14, status=1, ipAttribution=)]
    2014-06-06 chenhongpeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=34393, encodeId=08093439315, content=这个当然, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:21:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932497, encodeId=3749193249ec0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 07 23:20:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941247, encodeId=18f0194124e0d, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 06 19:20:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006922, encodeId=cd562006922e4, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Jun 24 08:20:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783229, encodeId=5b2c1e83229ce, content=<a href='/topic/show?id=2f7d4e816b' target=_blank style='color:#2F92EE;'>#CJASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4781, encryptionId=2f7d4e816b, topicName=CJASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Aug 14 13:20:00 CST 2014, time=2014-08-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=34393, encodeId=08093439315, content=这个当然, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:21:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932497, encodeId=3749193249ec0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Wed Jan 07 23:20:00 CST 2015, time=2015-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941247, encodeId=18f0194124e0d, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Jun 06 19:20:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006922, encodeId=cd562006922e4, content=<a href='/topic/show?id=52ad6902144' target=_blank style='color:#2F92EE;'>#生存获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69021, encryptionId=52ad6902144, topicName=生存获益)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Tue Jun 24 08:20:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783229, encodeId=5b2c1e83229ce, content=<a href='/topic/show?id=2f7d4e816b' target=_blank style='color:#2F92EE;'>#CJASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4781, encryptionId=2f7d4e816b, topicName=CJASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Thu Aug 14 13:20:00 CST 2014, time=2014-08-14, status=1, ipAttribution=)]
    2014-08-14 ay2000fy

相关资讯

肾衰和感染或仍是SLE患者主要死因

  巴西一项研究显示,与发达国家不同,肾衰和感染性疾病是该国SLE患者的最常见死因。谨慎使用免疫抑制治疗和积极治疗心血管合并症对改善SLE生存率至关重要。论文发表于《风湿病杂志》[J Rheumatol 2012,39(3):496]。   该研究的主要结果为,以SLE为基础死因者的平均死亡年龄为35.77岁[标准差(SD)为15.12],其主要的非基础死因包括肾衰、循环系统

CO中毒并横纹肌溶解致急性肾衰

        病例摘要:   患者,男,55岁,既往体健。因尿少伴乏力三天入院,患者三天前夜间睡眠时在床边放置煤炭炉且通风不良,清晨被家人发现时神态不清,床边有呕吐物,在当地卫生所治疗两天后,意识恢复,但尿量明显减少,入院前24 h尿量低于400ml,尿呈酱油色 。   呼吸21次/分,血压144/80 mmHg,脉搏8

CJASN:严重抑郁或增糖尿病患者肾衰风险

     美国学者 Bessie A. Young研究发现,严重抑郁症状与糖尿病患者终末期肾脏病(ESRD)发生风险较高相关。论文3月27日在线发表于《美国肾脏病学会临床杂志》(Clin J Am Soc Nephrol)。     该研究共纳入3886例糖尿病门诊患者,并收集抑郁症状和糖尿病自我护理模式等资料,评估

中国人群高血压流行现状与趋势

  世界卫生组织指出人口老化、快速城市化和不健康生活习惯的全球化使得富国和穷国面临着同样的健康问题。最显著的例子是慢性非传染性疾病,例如心血管疾病、肿瘤、糖尿病和慢性肺病,已经超过传染性疾病成为全世界的主要死因。高血压是导致心脏病、脑卒中、肾衰、过早死亡及生活功能障碍的重要原因。2013年世界卫生日的主题就是控制高血压。    预防血压升高、对高血压患者的早期检出与诊断、给予合适的干预